Drug
1-methyl-d-tryptophan
1-methyl-d-tryptophan is a pharmaceutical drug with 5 clinical trials. Historical success rate of 75.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
4
80%
Ph not_applicable
1
20%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Withdrawn1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (80.0%)
N/A1 (20.0%)
Trials by Status
withdrawn120%
completed360%
terminated120%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_1
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
NCT00739609
completedphase_1
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
NCT01042535
withdrawnnot_applicable
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
NCT01302821
completedphase_1
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
NCT00567931
completedphase_1
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
NCT01191216
Clinical Trials (5)
Showing 5 of 5 trials
NCT00739609Phase 1
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
NCT01042535Phase 1
Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
NCT01302821Not Applicable
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
NCT00567931Phase 1
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
NCT01191216Phase 1
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5